

32nd Annual Cancer Progress Conference, May 4th – 6th 2021

DAY ONE: MAY 4, 2021

9:00 – 9:15 am

Opening Remarks

Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting

9:15 – 10:00 am

Keynote: Engineering the Future: Next Gen Platforms in Oncology

Speaker: Daniel S Chen, MD, PhD, Chief Medical Officer, IGM Biosciences

After a decade where cancer immunotherapy has emerged as an important therapeutic approach for patients battling terminal cancer, next generation approaches to cancer immunotherapy beyond the PD-1/PD-L1 pathway have yet to clearly and broadly emerge. What are the challenges that remain to be overcome, so that the human immune response can eradicate cancer in more patients? And how are efforts in engineering therapeutics allowing us to move beyond simplistic approaches to inhibition of a biologic target? These concepts, and examples of next generation therapies, will be presented.

10:15 – 11:30 am

Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors

This session will focus on perhaps the most active area of drug development in Oncology: the effort to improve upon outcomes with checkpoint inhibitors (CPI) by combining agents post failure of the checkpoint with the CPI to resensitize the tumor microenvironment and enable patients to continue to derive benefit from immunotherapies. A diverse array of MOAs and therapeutic approaches are being harnessed to try to address this daunting task, ranging from new checkpoint inhibitors, costims and multifunctional biologics, to agents targeting other “bad actors” and pathways in the TME including modulators of innate immunity. In addition, oncolytic viruses, agents driving immunogenic cell death, cancer vaccines and cell therapies are also looking to provide value in this checkpoint-experienced space. Finally, an alternative approach, but one requiring more wherewithal (financially and in time) is to bring such new agents forward into combination with checkpoint right at the start, into upfront settings.

Moderator: Jeffrey M. Bockman, PhD, EVP, Oncology Practice Head, and James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting

Panelists:

- Michael A Curran, PhD, Associate Professor, Dept. of Immunology
Founder, ImmunoGenesis, Inc, The University of Texas MD Anderson Cancer Center, Department of Immunology, Division of Basic Sciences
- Kapil Dhingra, MB, BS, Managing Member, KAPital Consulting LLC
- Louis Kayitalire, MD, CMO, F-star Therapeutics
- Laurent Levy, PhD, CEO Nanobiotix
- Michael J. Newman, PhD, President & CEO, Decoy Biosystems, Inc.
- Emmett Schmidt, MD, PhD, VP, Clinical Oncology, Lead, External Collaborations Oncology Early Development, Merck and Co.
- Thomas Schuetz, MD, PhD, CEO and Co-founder, Compass Therapeutics

11:45 am – 1:00 pm

Multifunctional Soluble Biologics: Binders, Binders Everywhere

As a therapeutic class, soluble biologics continue to represent a significant area of pipeline activity and innovation, particularly in immuno-oncology. Improvements in screening tools and protein engineering enables identification of novel targets and optimal binders with superior reactivity, fine-tuning of affinity and avidity, also introduces approaches to design therapies with multiple functionalities beyond the limitations of natural monoclonal antibodies. For this panel discussion, we would like to consider the unique offerings of multi-targeted biologics and think through development hurdles. We will also reflect on how to meaningfully differentiate and inflect value across key stakeholders. What are key unmet needs in immuno-oncology that multi-functional biologics can potentially address? Are there specific targets or combinations that are especially well-suited for multi-functional soluble biologics to pursue? What are key strategies to improve on toxicities and broaden application into solid tumors? What are key learnings from recent challenges to advance other multi-functional antibodies in the clinic?

Moderator: James T. Lee, PhD, Principal, Oncology Lead, and Serom Lee, PhD, Senior Consultant, Cello Health BioConsulting

Panelists:

- Philip Bland-Ward, PhD, Chief Development Officer, Crescendo Biologics Ltd
- Neil Brewis, PhD, CSO, F-star Therapeutics
- Björn Frendeus, CSO, BioInvent International AB
- Valerie Odegard, PhD, CSO, Silverback Therapeutics
- Taylor H. Schreiber, MD, PhD, CEO & Co-Founder, Shattuck Labs, Inc

1:00 – 1:30 pm

Break for Lunch

1:30 – 2:45 pm

Tumor Agnostic Development

We believe that tumour agnostic approval will replace the traditional tumour and stage specific path. The FDA approval pembrolizumab for MSI tumours, and both Larotrectinib and Entrectinib for NTRK fusions has set the path.

Richard Pazdur, MD, Acting Director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and Director of the FDA's Oncology Center of Excellence quotes re the pembrolizumab approval: "The review of pembrolizumab for this indication was based on overall response rate and durability of response. Of the 149 patients who received pembrolizumab in these studies, 39.6% had a complete or partial response. For 78% of those patients, the response lasted 6 months or longer."

To further quote Dr Pazdur: "This new indication represents a shift in our evaluation of therapies. The approval moves us away from the strict disease-site indication, such as breast, colon, or lung cancer, to a site-agnostic indication. It changes how we may define cancer—the disease is no longer being solely determined by its site of origin or pathologic diagnosis. It is now defined by the presence of a specific biomarker." This will lead to much smaller trial sizes and accelerated drug development and approval.

Moderator Julie R. Gralow, MD, FACP, FASCO, EVP & CMO, American Society of Clinical Oncology Association for Clinical Oncology

Panelists:

- David Hyman MD, CMO, Loxo Oncology at Lilly
- Brian Leyland Jones, MB BS, PhD, CMO, National Foundation For Cancer Research
- Jean-François Martini, PhD, MSc, Sr Director, Translational Oncology Lead, Global Product Development, Pfizer Inc
- Mark Pegram, MD, Professor of Medical Oncology, Stanford Comprehensive Cancer Institute, Stanford University
- Richard L. Schilsky, MD, FACP, FSCT, FASCO, Professor Emeritus, University of Chicago

3:00 – 4:15 pm

Accelerated Development Paths

Moderator: Brian Leyland Jones, MB BS, PhD, CMO, National Foundation for Cancer Research

Panelists:

- Nora Ku, MD, VP, Medical, Loxo Oncology at Lilly
- Ralph E. Parchment, PhD, Director, Clinical Pharmacodynamic Biomarkers Program Frederick National Laboratory for Cancer Research National Cancer Institute, NIH
- Sarah Warren, PhD, Senior Director, Translational Science, NanoString Technologies
- Professor Paul Workman, CEO & President, The Institute of Cancer Research, London

4:30 – 5:45 pm

Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?

We are seeing an amazing convergence of platforms and technologies as academic labs and startups continue to innovate around advanced engineering of biologics. This synthetic biology, which I mean here to point to the synthesis of various technologies, involves therapies that display engineering into the “modality” some multifunctionality and often controllability. This synthesis of technologies – from protein to RNA engineering, or gene therapy or editing, also harnesses advances in drug delivery with nanoparticles and targeting moieties to home the modality to specifically the tumor or to immune cells. The emerging space of endogenous reprogramming represents a continuum and extension of current approaches from ex vivo modification of cell therapies to platforms straddling ex vivo and in vivo modulation of immune cells via redirecting biologics and adaptor molecules, to truly in situ manipulation of the tumor and/or immune cells. As such, endogenous reprogramming often must therefore layer on risk, IP, and a certainly complexity that enables the unique multifunctionality that is a great part of their value proposition, and hence careful consideration of targets, target cells, and indications becomes paramount.

Moderator: Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting

Panelists:

- Jacob Becraft, PhD, CEO, Co-founder, Strand Therapeutics
- Mary Haak-Frendscho, PhD, President & CEO, Spotlight Therapeutics
- Stephan Matthias, MD PhD, Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Center
- Derek Ostertag, PhD, SVP, Head of R&D, Abintus Bio

5:45 pm

Day 1 Cancer Progress 2021 Conference Conclude

DAY TWO: MAY 5, 2021

9:00 – 9:15 am Opening Remarks: Review of Day 1

James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting

9:15 – 10:00 am Keynote Address: Off-the-shelf CAR-engineered NK cells for the treatment of cancer

Speaker: Katy Rezvani, MD, PhD, Sally Copper Murray Endowed Chair in Cancer Research Professor of Medicine, Chief, Section of Cellular Therapy, Director for Translational Research Medical Director, SCT Laboratory and the GMP Laboratory, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center

Dr. Rezvani will discuss a new frontier in NK cell therapeutics: engineering NK cells with chimeric antigen receptors. She will discuss the opportunities and challenges of NK cell CAR engineering, and present pre-clinical and early phase clinical data on cord blood-derived NK cells expressing CD19 CAR and IL-15 to enhance their in vivo persistence in patients with relapsed or refractory blood cancers. In addition, she will discuss novel strategies for the gene editing of CAR NK cells to enhance their function by targeting immune checkpoints.

10:15 – 11:30 am Allogeneic Cell Therapy: Stocking the Shelf Part I (NKs, NKTs)

From the earliest days of hematopoietic stem cell transplant to the present-day age of engineered modalities, allogeneic cells have always represented a unique set of entities versus their patient-derived (autologous) counterparts, both in terms of their logistical and clinical attributes. Whereas auto therapy can and should persist in the patient for a long time, in-kind allo assets may not due to the challenge of rendering cells invisible to the host immune system. On the other hand, allo cells offer the possibility of simplified supply chains, reduced COGS, competitive pricing, repeat dosing, improved batch-to-batch consistency, and graft-mediated antitumor effects not achievable with auto cells. Allo platforms come in many flavors, from donor-derived T-cells to umbilical cord- or iPSC-derived NK cells, not to mention rarer innate-like cell types (gamma-deltas, NKTs). The extent to which these different approaches, and indeed the overarching endeavor of allo cells as a whole, will achieve clinical and commercial success remains to be answered, but with the breakneck pace of innovation and clinical development, we will not need to wait much longer to find out.

Moderator: Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting

Panelists

- Lung-I Cheng, PhD, Head of Global Value and Access, Cell Therapies, Takeda Oncology
- Kurt Gunter, MD, CMO, kuur Therapeutics
- Kaouthar Lbiati, MD, VP, Corporate Strategy, Cytovia Therapeutics
- Alan Trounson, MSc, PhD, CEO and Executive Director, Cartherics

11:45 – 1:00 pm Allogeneic Cell Therapy: Stocking the Shelf Part II (Traditional T-cells, Gamma-deltas)

From the earliest days of hematopoietic stem cell transplant to the present-day age of engineered modalities, allogeneic cells have always represented a unique set of entities versus their patient-derived (autologous) counterparts, both in terms of their logistical and clinical attributes. Whereas auto therapy can and should persist in the patient for a long time, in-kind allo assets may not due to the challenge of rendering cells invisible to the host immune system. On the other hand, allo cells offer the possibility of simplified supply chains, reduced COGS, competitive pricing, repeat dosing, improved batch-to-batch consistency, and graft-mediated antitumor effects not achievable with auto cells. Allo platforms come in many flavors, from

donor-derived T-cells to umbilical cord- or iPSC-derived NK cells, not to mention rarer innate-like cell types (gamma-deltas, NKTs). The extent to which these different approaches, and indeed the overarching endeavor of allo cells as a whole, will achieve clinical and commercial success remains to be answered, but with the breakneck pace of innovation and clinical development, we will not need to wait much longer to find out.

Moderator: Michael C. Rice, MS, MBA, Head of Advanced Therapeutics, Cello Health BioConsulting

Panelists:

- Greg Block, PhD, SVP Corporate Development, Notch Therapeutics
- Rachel Haurwitz, PhD, CEO & Founder, Caribou Biosciences, Inc.
- Sandy Hayes, PhD, Senior Director, T cell Immunology/Translational Medicine, Adicet Therapeutics
- Ajla Hrlje, PhD, Director, Head of Strategic Alliances, Immatics Biotechnologies

1:00 – 1:30 pm

Break for Lunch

1:30 – 2:45 pm

Cell Therapy in Solid Tumors: Freedom of the Open Road

Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry, investor, and oncology stakeholders alike for their perceived ability to drive a robust and tailored antitumor immune response across varied oncology settings. Given the amount of crowding around a limited number of heme malignancy targets (CD19, BCMA), however, competition in this arena will continue to be prohibitive for all but a few until the utility of cell therapies finally begins to encompass at least some if not significant potential across solid tumors. Early signs of clinical success from TILs and TCR-T cells have underscored potential for broader utility across solid tumor settings, but wins will be hard fought until replicable and scalable modalities find their footing.

Moderator: Joel S. Sandler, PhD, Principal, Cancer Cell Therapy Lead, Cello Health BioConsulting

Panelists:

- Sharon Benzeno, PhD, MBA, Chief Business Development Officer, Adaptive Biotechnologies Corp.
- John Delyani, PhD, MBA, VP, Corporate Development, Tminuty Therapeutics Inc
- Stanley R. Frankel, MD, FACP, CMO, Cytovia
- Kirsten Kester, VP, BD, Obsidian Therapeutics, Inc.
- Mythili Koneru, MD, PhD, CMO, Marker Therapeutics
- Peter Sandor, MD, MBA, SVP, Primary Focus Lead Immuno-oncology, Astellas

3:00 – 4:15 pm

Validating New Platforms: Clinical Pain, Commercial Gain

Cell therapy lends itself to countless technical modifications, each with their own theoretical value propositions positioned to address shortcomings of existing modalities. Platform technologies are proliferating at a dizzying pace as well-funded investigators discover and spin out novel technologies for translation and value-inflection. All the while, investors and would-be partners continue to rotate funds into the cell therapy arena as the search of novel means to address unmet needs marches forth in a field that has yet to feel the pinch of pricing restrictions. Innovative companies with a mandate to develop new platforms face a bevy of strategic questions, most pressingly that of how best to validate the platform without sacrificing time or commercial potential from lead clinical candidates. Chief among such

considerations is positioning strategy – choice of targets, indications for lead programs – the shaping of which dictates where one sits on the spectra of clinical and commercial risk.

Moderator: Joel S. Sandler, PhD, Principal, Cancer Cell Therapy Lead, Cello Health BioConsulting

Panelists:

- Robert Ang, MD, MBA, President & CEO, Vor Bio Pharm
- Debora Barton, MD, CMO, Carisma Therapeutics Inc.
- Lawrence Lamb, Phd, Scientific Co-Founder & CSO, in8bio
- Jan ter Meulen, MD, PhD, CSO, Obsidian Therapeutics, Inc.
- Arndt Schottelius, MD, PhD, CSO, Affimed
- Daniel A. Shelly, MBA, VP Business Development and Alliances, Prescient Therapeutics Limited

4:30 – 5:45 pm

Counterpoint to Over-engineering: Bauhaus Minimalism in an Era of More Opulent T-cell Architecture

Engineered (iPSC-derived, CAR-modified, universal adaptor-driven) cells have captured the lion's share of investor and partnering attention to date in the dash to find the next big thing in cell therapy. At the same time, a host of innovators are positioned to advance novel technologies comprised of minimally manipulated cells ('trained' cells, TILs, MILs) or those engineered to retain native features present in unmodified host immune cells (intracellular TCR signaling, costimulatory domains). These companies are collectively taking the position that retention of native, 'beneath-the-hood' signaling is ultimately going to be key to achieving potency, durability, and safety of administered cell therapies across a broader range of indications than those addressable with their more overtly-engineered counterparts. Beyond theoretical rationale, these companies are generating mounting bodies of preclinical and early clinical data to support their case. A key question is whether these biological differences are sufficient to translate into clinically-meaningful benefit, either as later entrants in more crowded indications or earlier movers in whitespace settings previously-deemed inaccessible to competing technologies.

Moderator: Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting

Panelists:

- Keith Bahjat, Sr Director Science, Cell Therapy Center of Excellence, Astellas
- Frank Borriello, MD, PhD, Founder & CEO, Alloplex Biotherapeutics
- Sabine Chlosta, MD, CMO, Triumvera
- Kimberly A. Noonan, PhD, MPH, EVP, CS&TO, Founder, WindMIL
- Paul D. Rennert, President & CSO, Aleta Biotherapeutics

Day 2 Cancer Progress 2021 Conference Concludes

DAY THREE: MAY 6, 2021

8:15 – 8:30 am

Opening Remarks: Review of Day 2

Joel S. Sandler, PhD, Principal, Cancer Cell Therapy Lead, Cello Health BioConsulting

8:30 – 9:45 am

Cross-border Dealmaking: China Importing/Exporting Trends and Challenges

China has undoubtedly become a powerhouse for dealmaking activity in the oncology space. Over the past 5+ years, the number of Chinese biotech and pharma invested in the oncology space have grown and portfolios have moved further away from the generic/life cycle play agents to more innovative therapeutics. Although there is a tendency by many Chinese companies to still go after the de-risked assets when looking to develop in China, those that are looking for growth in the global markets are looking to become the first wave of new targets and asset/modalities. In-licensing activities for Chinese biopharma had previously been more focused on late stage/marketed assets and now we are starting to see companies filling the backlog in their portfolio with early assets. Out-licensing activities of Chinese biotech have heated up in the last year or so, with some major out-licensing of not just validated target classes (PD-1/L1), but also of novel FIC assets (CD47/I-Mab). Within the context of these trends and the ongoing pandemic, will dealmaking slow down? Where will China dealmaking go next? How should those looking to deal with Chinese biopharma position themselves to gain interest?

Moderator: James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting

Panelists:

- Jeff Kmetz, CBO, Ascentage Pharma
- Fernando Sales, PhD, SVP, Head of US & EU BD, I-Mab Biopharma
- Guillaume Vignon, SVP, BD, BeiGene
- Ed Zhang, Venture Partner, Hillhouse Capital Management

10:00 – 11:15 am

Investing in the *Emerald City* of Oncology Innovation: Platforms & Modalities & Targets, Oh My!

Moderator: Mark Simon, Partner and Co-Founder, Torreya

Panelists:

- Jay Campbell, Managing Director, Clinical Accelerator and Venture Fund Cancer Research Institute
- Margarita Chavez, JD, Managing Director, AbbVie Ventures
- Maha Katabi, PhD, CFA, General Partner, Sofinnova Investments
- Carolyn Ng, Managing Director, Vertex Ventures HC
- Steven C. Quay, MD, PhD, Chairman & CEO, Atossa Therapeutics
- Yaping Shou, MD, PhD, Venture Partner, Lilly Asia Ventures
- Anna Turetsky, Principal, Venture Investments, The Mark Foundation

11:30 am – 12:45 pm

Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML

Moderator: Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting

Panelists:

- Kenneth C. Anderson, MD, Dana-Farber Cancer Institute
- Lee Greenberger, PhD, CSO & SVP, The Leukemia & Lymphoma Society
- Daniel A Pollyea, MD MS, Associate Professor of Medicine, Division of Hematology, University of Colorado School of Medicine

12:45 – 1:15 pm

Break for Lunch

1:30 – 2:45 pm

Let's Make a Deal in Oncology: What's Behind the Doors & Who Has the Keys?

Moderator: Jeremy Goldberg, Operating Partner, Arsenal Capital Partners

Panelists:

- John DeYoung, VP, Worldwide BD, Oncology Business Unit, Pfizer Inc.
- Philippe Lopes-Fernandes, EVP, CBO, Ipsen
- Christopher Mortko, Associate VP, Business Development and Licensing, Merck & Co, Inc
- Peter Sandor, MD, MBA, SVP, Primary Focus Lead Immuno-oncology, Astellas
- Deepa Talpade, VP, BD&L and Alliance Management, Oncology, Bayer

3:00 – 4:15 pm

Where Progress Against Cancer Hits the “Pay Wall”

For a decade now, the “value” panel during Cancer Progress has delivered a spirited and often, controversial, discussion around the subject of the costs and associated value of cancer drugs. Nevertheless, despite numerous thoughtful solutions proposed, both market-based and legislative, and debated by many of the participants (including those joining us again this year), we remain largely stuck where we started. By stark contrast, in the time since this panel first convened, a head spinning array of novel therapies have appeared on the market. These therapies increasingly rely on novel and complex delivery platforms, in particular adoptive cellular therapies and, in totality (as well evidenced through this conference), represent a diverse range of therapeutic approaches as well as degrees of personalization that are unprecedented and unmatched in any other disease category.

But there has been a dearth of innovation directed at addressing the seemingly inexorable and exponential increases in the costs of these therapies, and the brutal impact, first and foremost on cancer patients and their families, but also to all societal stakeholders. Likewise lacking on the innovation front is progress with business models that can cost effectively deliver these therapies while producing convincing demonstration of value. Moreover, aside from the highly visible costs of therapy, there remains an “elephant in the backseat” problem: the overwhelming majority of these costs are associated with use in patients with cancers already well advanced (metastatic) at time of diagnosis, despite significant advances in both the access to, turnaround time and cost of next gen sequencing (NGS).

This panel of experts all of whom are continuing to work hard to bring desperately needed innovation to pricing, value and access, will discuss the continuing barriers to progress and how they ultimately can and will be surmounted. Among topics to be discussed:

- Advances in payment models
- Advances in assessing value
- Opportunities and challenges of shifting industry and academic focus from treating advanced disease to early intervention

Moderator: Ed Saltzman, Executive Chairman, Cello Heath BioConsulting

Panelists:

- Ron Akehurst, Chairman, BresMed Health Solutions
- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Michael Kolodziej, MD, VP and CIO, ADVI Health
- Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability; Head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center

4:30 – 5:30pm**Battle of the Modalities- The Sequel**

In an era characterized by translation of novel scientific concepts toward an array of competing clinical candidates, treatment algorithms across the spectrum of cancer types are on the verge of confronting a proverbial “nice problem to have,” with multiple modalities and products therein from which to choose. Old meets new against a backdrop of unabating unmet need and burgeoning financial strain. Which modalities can be combined, sequenced, or replaced? Will any reign supreme? At what point does cost and convenience outweigh efficacy and tolerability? Will there ever be enough evidence to support clinical decision-making among different modalities? If any of these questions pique your interest, please join the organizers of Cancer Progress for one final session during which we will engage in a collegial discussion – interspersed at times with respectful debate, juvenile bickering, and perhaps some poetry slam – on the all-important topic of modalities in the modern age of cancer treatment.

Moderator: Serom Lee, PhD, Senior Consultant, Cello Health BioConsulting

Panelists:

- Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting
- James T. Lee, PhD, Principal, Oncology Lead Cello Health BioConsulting
- Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting
- Joel S. Sandler, PhD, Principal, Cancer Cell Therapy Lead, Cello Health BioConsulting

Cancer Progress 2021 Conference Concludes